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centration-dependent killing. The PAE of doxycycline is clini-
cally unimportant since adequate serum concentrations are
maintained for the duration of the dosing interval if given on a
12 h or 24 h basis.
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Gastroenteritis caused by nontyphoidal salmonellae is a com-
mon entity, usually self-limiting and not requiring antibiotic
treatment. However, in immunocompromised patients or in
invasive infections rapid and efficacious treatment is required.
The increase in resistance displayed by this pathogen to the
antibiotics classically used in salmonellosis (ampicillin, cotri-
moxazol, chloramphenicol, etc.) has caused ciprofloxacin to be
considered the antibiotic of choice in the treatment of invasive
salmonellosis.
Resistance to fluoroquinolones in non-typhoidal sal-
monellae is infrequent, with very few cases reported in the
literature [1–5]. However, there are reports of clinical failures
in the treatment with ciprofloxacin of strains that, although
susceptible, have increased MICs for this antibiotic [6,7].
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 265–282
6. Cunha BA. Current concepts in the antibiotic therapy of legion-
naires’ disease. Drugs Today 1997; 33: 213–20.
7. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Post-antibiotic
suppression of bacterial growth. Rev Infect Dis 1981; 3: 28–37.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters:
rationale for antibacterial dosing of mice and men. Clin Infect Dis
1998; 26: 1–12.
9. Craig WA, Gudmundsson S. Post-antibiotic effect. In: Lorian V.
ed. Antibiotics in laboratory medicine, 4th edn. Baltimore: Williams
and Wilkens, 1996: 296–329.
10. Cars O, Odenholt-Tornqvist I. The post-antibiotic sub-MIC effect
in vitro and in vivo. J Antimicrob Chemother 1993; 31: 159–66.
11. Craig WA. Interrelationship between pharmacokinetics and phar-
macodynamics in determining dosage regimens for broad-spectrum
cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89–96.
12. Totsuka K, Shimizu K. In vitro and in vivo post-antibiotic effects
(PAE) of CL 31, 928 (DMG–DMDOT), a new glycylcycline
against Staphylococcus aureus. In: 34th Interscience Conference on
Antimicrobial Agents and Chemotherapy. Washington DC: American
Society of Microbiology, 1994; 179: Abstract F114.
13. Walker R, Andes D, Ebert S, Conklin R, Craig WA. Phar-
macodynamic comparison of 6 dimethyl 6-deoxytetracycline
(DMDOT) and minocycline in an animal infection model. In:
34th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Washington DC: American Society of Microbiology, 1994; 179:
(Abstract) F116.
The National Committee for Clinical Laboratory Standards
(NCCLS) [8] considers as susceptible to ciprofloxacin all those
strains of Salmonella enterica which have MICs  1 mg/L.
According to this criterion, ciprofloxacin resistance in the vari-
ous species of S. enterica is exceptional [1–4]. However, there
are authors who recommend adjusting the cutoff points to
consider susceptible only those strains with MICs0.125 mg/L
[1,9].
Resistance to nalidixic acid in Salmonella enterica, although
of slight clinical importance given its infrequent use in the
treatment of salmonellosis, may serve as the marker of a future
increase in resistance to fluoroquinolones, as has happened with
Escherichia coli [10].
In this work we studied the resistance patterns to nalidixic
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acid and ciprofloxacin and to another eight antibiotics in 187
strains of Salmonella enterica isolated in clinical samples over a
period of six months in 1998, comparing with the resistance to
quinolones observed among the various serotypes.
We studied 187 strains of Salmonella enterica isolated in clinical
samples in our hospital over a period of 6 months during 1998.
Serological identification was performed with specific antisera
(Difco Laboratories, Detroit, MI, USA) according to the Kauff-
man–White scheme [11]. The strains were divided into three
groups to facilitate the comparison of susceptibility results. Sal-
monella enterica ssp. enterica serotype Enteritidis and S. enterica
ssp. enterica serotype Typhimurium made up groups one and
two, respectively, and group three included the rest of the
serotypes. The minimum inhibitory concentrations were deter-
mined for nalidixic acid (Sigma, St Louis, MO, USA), cip-
rofloxacin (Bayer, Wuppertal, Germany), ampicillin (A)
(Smith-Kline Beecham, Toledo, Spain), amoxycillin/clavulanic
acid (AC) (Smith-Kline Beecham), cefotaxime (CT) (Sigma),
chloramphenicol (CL) (Sigma), tetracycline (TE) (Sigma), gen-
tamicin (G) (Sigma), trimethoprim (TP) (Roche, Basle, Swit-
zerland), sulfamethoxazole (SM) (Roche) and streptomycin
(ST) (Sigma) using the agar dilution method in Mueller–Hinton
agar (BBL, Beckton Dickinson, Cockeysville, MD, USA) fol-
lowing the criteria of the NCCLS. Final concentrations were
0.015–4 mg/L for ciprofloxacin, 0.5–32 mg/L for nalidixic
acid, 8–256 mg/L for ampicillin, 4/2–32/16 mg/L for amoxy-
cillin/clavulanic acid, 0.03–1 mg/L for cefotaxime, 1–16 mg/L
for trimethoprim, 16–256 mg/L for sulfamethoxazole, 1–
8 mg/L for gentamicin, 1–16 mg/L for tetracycline and 1–
32 mg/L for streptomycin. The plates were inoculated with a
Steers replicator and incubated at 35 °C for 17 h. Control strains
used were Escherichia coli ATCC 35218 and Escherichia coli
ATCC 25922. The results were interpreted according to the
cutoff points established by the NCCLS. In the case of cip-
rofloxacin cutoff points of 0.25 mg/L and 0.125 mg/L
were also used.
Of the 187 strains isolated, 119 (63.6%) were identified as
S. Enteritidis, 40 (21.4%) as S. Typhimurium and the remaining
28 (15%) belonged to other serotypes.
The MICs obtained with control strains were always within
established limits. The percentages of resistance to antibiotics
not belonging to the fluoroquinolone group are shown in
Table 1. We found that S. Typhimurium is significantly more
Table 1 Resistance percentages
(%R) for the different
serotypes to nine antibiotics not
belonging to the quinolone
group
A AC CT TP SM TE CL G ST
S.E. (%R) 10.1 2.5 0 0.8 0 0 0 0 0
S.T. (%R) 77.5 55 0 35 90 87.5 80 17.5 95
Others (%R) 35.7 25 0 3.6 3.6 39.3 28.6 0 39.3
S.E., Salmonella Enteritidis. S.T., Salmonella Typhimurium.
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resistant (P  0.05) than S. Enteritidis to all except cefotaxime,
to which none of the strains belonging to any of the serotypes
was resistant.
The results obtained for the fluoroquinolones are shown in
Table 2 in the form of interval, MIC50, MIC90 and resistance
percentage according to serotype. Of the 187 strains studied,
72 (38.5%) were resistant to nalidixic acid. The percentage
varied from 27.5% for S. Typhimurium to 43.7% for S. Enter-
itidis, whereas the rest of the serotypes, considered as a group,
showed 32.1% resistance to nalidixic acid.
No strains showed either resistance or intermediate sus-
ceptibility to ciprofloxacin, according to the criteria established
by the NCCLS (MIC  1 mg/L).
Table 3 shows the relationship between resistance to nal-
idixic acid and the increase in the MIC for ciprofloxacin. Of
the strains that were resistant to nalidixic acid, the percentage
of isolates with MIC  0.125 mg/L for ciprofloxacin was 50%
for S. Enteritidis, 45.4% for S. Typhimurium and 100% for the
group made up of the rest of the serotypes. None of the strains
susceptible to nalidixic acid had an MIC  0.125 mg/L for
ciprofloxacin.
The percentages of resistance to ciprofloxacin according to
different cutoff points are shown in Table 4. Using the cutoff
point recommended by some authors (resistance with
MIC  0.125 mg/L), resistance to ciprofloxacin would reach
five of 119 strains (4.2%) for S. Enteritidis, five of 40 (12.5%)
for S. Typhimurium and six of 28 (21.4%) for the rest of the
serotypes. However, considering resistance with MIC  0.125,
the resistance percentages would vary significantly for S. Enter-
itidis, 21.8%, and in the group of the rest of the serotypes,
32.1%, although there would be no variation for S. Typhi-
murium.
The increase in antibiotic resistance displayed by isolates of
S. enterica has recently been described in several works [12–
14].This increase predominantly affects the serotype S. Typhi-
murium definitive type 104 (DT104) which displays resistance
to ampicillin, chloramphenicol, streptomycin, sulphonamides
and tetracyclines (resistance ACSSuT) [13,15]. In our experi-
ence S. Enteritidis is considerably more prevalent than S.
Typhimurium (63.6 versus 21.4%). These figures are in agree-
ment with the data obtained in other studies carried out in
Spain [12,16], but differ from those obtained in other countries
such USA, Ireland, Finland, etc. [9,13,17] where the prevalence
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Table 2 Interval, MIC50, MIC90 in mg/L and resistance percentage for 187 strains of Salmonella enterica
Nalidixic acid Ciprofloxacin
Range MIC50 MIC90 % R Range MIC50 MIC90 % R
S. E. (n = 119) 2  32 8 32 43.7 0.015–0.5 0.015 0.12 0
S. T. (n = 40) 2  32 8 32 27.5 0.015–0.5 0.015 0.5 0
Others (n = 28) 2  32 8 32 32.1 0.015–0.5 0.015 0.5 0
Total (n = 187) 2  32 8 32 38.5 0.015–0.5 0.015 0.5 0
S.E., Salmonella Enteritidis. S.T., Salmonella Typhimurium.
Table 3 Relationship between
nalidixic acid resistance and
increased MICs for ciprofloxacin
Nalidixic acid susceptible Nalidixic acid resistant
CP  0.125a CP  0.125a R (%)b CP  0.125a CP  0.125a R (%)b
S.E 67 0 0 26 26 50
S.T 29 0 0 6 5 45.4
Others 19 0 0 0 9 100
S.E., Salmonella Enteritidis. S.T., Salmonella Typhimurium; , CP, ciprofloxacin.
a MIC measured in mg/L.
b Resistant percentage with the cutoff point at 0.125 mg/L.
Table 4 Percentage of susceptibility to nalidixic acid and ciprofloxacin (Cipro) according to different cutoff points
Species % R nalidixic acid % R Cipro (NCCLS) % R Cipro (0.125) % R Cipro (0.125)
S.E (n = 119) 43.7 (n = 52) 0 4.2 (n = 5) 21.8 (n = 26)
S.T. (n = 40) 27.5 (n = 11) 0 12.5 (n = 5) 12.5 (n = 5)
Others (n = 28) 32.1 (n = 9) 0 21.4 (n = 6) 32.1 (n = 9)
Total (n = 187) 38.5 (n = 72) 0 8.5 (n = 16) 21.4 (n = 40)
S.E., Salmonella Enteritidis. S.T., Salmonella Typhimurium.
of the two serotypes is nearly equal or even where the preva-
lence of S. Typhimurium is superior. However, the pattern and
frequency of resistance that we found in S. Typhimurium
coincides with these studies [13,17] and which, in our case,
reached 77% combined ACSSuT resistance. This resistance
phenotype has been associated with the DT104 [4,13] so that
it seems probable that this phage type is also widely disseminated
among the strains of S. Typhimurium isolated in our area.
Resistance to nalidixic acid on the part of S. enterica has
previously been described in various works, both in animals
isolates [18] and in human isolates [9,19]. In all cases S. Typhi-
murium is found to be more resistant than S. Enteritidis, and
frequently displays associated multi-resistance. In the present
work we found a high prevalence of resistance to nalidixic acid
in all serovarieties of S. enterica, reaching 43.7% for S. Enteritidis
and 27.5% in S. Typhimurium. In addition, in S. Enteritidis,
this frequently appeared as single resistance. With regard to
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S. Typhimurium, these figures are similar to those recently
described by Hakanen et al. [9] in strains of this serotype which
they denominate foreign. However, the high overall resistance
(38.5%) is noteworthy and particularly, the fact that this is
largely accounted for by S. Enteritidis, an infrequent finding
since, as occurs with other antibiotics, resistance to quinolones
has almost always been associated with S. Typhimurium.
Using the cutoff points established by the NCCLS no strain
was resistant to ciprofloxacin. However, a significant increase
in the MICs for ciprofloxacin was observed in the nalidixic
acid-resistant strains in comparison with the nalidixic acid-
susceptible strains.
The increase in resistance to nalidixic acid serves to draw
our attention to the possible appearance of resistance to the
fluoroquinolones in the near future, as occurred with Escherichia
coli. The clinical significance of this reduction in susceptibility
to ciprofloxacin has still to be demonstrated. The existence of
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therapeutic failures with ciprofloxacin against strains with MICs
between 0.125 and 1 mg/L [6,7] has led some authors to recom-
mend a reconsideration of the cutoff point which should,
according to them, be established at 0.125 mg/L.
In our study, if we considered as resistant those strains with
MIC  0.125 mg/L, we would obtain an overall resistance to
ciprofloxacin of 8.5%, which would vary from 12.5% for S.
Typhimurium to 4.2% for S. Enteritidis. These figures coincide
with those recently published by Hakanen et al. [9] in strains
of foreign origin isolated in Finland, demonstrating that S.
Typhimurium is significantly more resistant to the fluoro-
quinolones than S. Enteritidis. However, the percentage of
resistance to nalidixic acid that we found in our study is higher
for S. Enteritidis and, as we have mentioned, an increase in the
MICs for ciprofloxacin is implicit in resistance to nalidixic acid.
It would therefore seem logical to expect a higher resistance to
ciprofloxacin as well, on the part of S. Enteritidis. If we estab-
lished the cutoff point at one dilution less, that is,
0.125 mg/L, we would obtain resistance percentages which
would more faithfully reflect the increase in MICs observed,
21.8% for S. Enteritidis and 12.5% for S. Typhimurium. This
marked difference obtained with the variation of only one
dilution in the cutoff point is due to the fact that the increase
in the MICs for ciprofloxacin is less in S. Enteritidis that in S.
Typhimurium, so that the mode of the MICs for ciprofloxacin
in nalidixic acid-resistant strains of S. Enteritidis is established
at precisely 0.125 mg/L. If it is decided to adjust the cutoff
point for ciprofloxacin, at present situated at 1 mg/L by the
NCCLS, to adapt it more exactly to what really happens with
these strains which are resistant to nalidixic acid and which
have reduced susceptibility to the fluoroquinolones, according
to our experience, it would seem logical to make adjustment
so that strains with MIC  0.125 mg/L are considered resistant
or intermediate, avoiding the classification of these isolates as
absolutely susceptible.
The high percentage of strains with decreased MICs for
the quinolones among non-typhoidal salmonellae isolates, and
primarily among S. Enteritidis which is the most common
serotype in our area, could become an important clinical prob-
lem, due to the habitual use of fluoroquinolones in the treat-
ment of invasive salmonellosis. The description of therapeutic
failures with ciprofloxacin in the treatment of non-typhoidal
salmonellae with increased MICs for this antibiotic, even when
less than 1 mg/L, suggest the convenience of adjusting the
present cutoff point. According to our data, a cutoff point
established at 0.125 mg/L would provide information more in
accordance with the true behaviour of non-typhi Salmonella
against the fluoroquinolones.
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